Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients-Reference-Cited by-同舟云学术

Daclatasvir and asunaprevir treatment improves liver function parameters and reduces liver fibrosis markers in chronic hepatitis C patients

Published:2016-02-16 Issue:8 Volume:46 Page:758-764
ISSN:1386-6346
Container-title:Hepatology Research
language:en
Short-container-title:Hepatol Res

Author:

Miyaki Eisuke¹²,Imamura Michio¹²,Hiraga Nobuhiko¹²,Murakami Eisuke¹²,Kawaoka Tomokazu¹²,Tsuge Masataka¹²,Hiramatsu Akira¹²,Kawakami Yoshiiku¹²,Aikata Hiroshi¹²,Hayes C. Nelson¹²,Chayama Kazuaki¹²

Affiliation:

1. Department of Gastroenterology and Metabolism, Applied Life Science, Institute of Biomedical and Health Science; Hiroshima University; Hiroshima Japan

2. Liver Research Project Center; Hiroshima University; Hiroshima Japan

Publisher

Wiley

Subject

Infectious Diseases,Hepatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/hepr.12621/fullpdf

Reference40 articles.

1. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus;Kiyosawa;Hepatology,1990

2. Prognosis of chronic hepatitis C: results of a large, prospective cohort study;Niederau;Hepatology,1998

3. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial;Manns;Lancet,2001

4. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection;Fried;N Engl J Med,2002

5. Current race in the development of DAAs (direct-acting antivirals) against HCV;De Clercq;Biochem Pharmacol,2014

Cited by 60 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Serum inducible protein 10 kDa/C‐X‐C motif chemokine 10 levels predict regression of M2BPGi‐based liver fibrosis after hepatitis C virus eradication by direct‐acting antiviral agents;Hepatology Research;2023-09-06

2. ケアマネジャーを対象としたC型慢性肝炎に関する全国アンケート調査;Kanzo;2023-07-01

3. Histological improvement in chronic hepatitis C-autoimmune hepatitis overlap syndrome by glecaprevir and pibrentasvir;Clinical Journal of Gastroenterology;2023-04-28

4. Quantitative image-based collagen structural features predict the reversibility of hepatitis C virus-induced liver fibrosis post antiviral therapies;Scientific Reports;2023-04-19

5. Short-term hepatocyte function and portal hypertension outcomes of sofosbuvir/velpatasvir for decompensated hepatitis C-related cirrhosis;Journal of Gastroenterology;2023-02-02